Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Baxter
Moodys
McKinsey
McKesson
Merck
Johnson and Johnson

Last Updated: October 20, 2019

DrugPatentWatch Database Preview

Drugs in Development Information for Molidustat

See Plans and Pricing

« Back to Dashboard

Drug Development Status for Molidustat: Sponsors, patents, clinical trial progress

Molidustat is an investigational drug.

There have been 9 clinical trials for Molidustat. The most recent clinical trial was a Phase 2 trial, which was initiated on November 30th 2017.

The most common disease conditions in clinical trials are Renal Insufficiency, Chronic, Renal Insufficiency, and Anemia. The leading clinical trial sponsors are Bayer and [disabled in preview].

There are eight US patents protecting this investigational drug and one hundred and seventy-four international patents.

Recent Clinical Trials for Molidustat
TitleSponsorPhase
Maintenance Treatment of Renal Anemia in Dialysis SubjectsBayerPhase 3
A Study of Molidustat for Treatment of Renal Anemia in Peritoneal Dialysis SubjectsBayerPhase 3
A Study of Molidustat for Correction of Renal Anemia in Dialysis SubjectsBayerPhase 3

See all Molidustat clinical trials

Clinical Trial Summary for Molidustat

Top disease conditions for Molidustat
Top clinical trial sponsors for Molidustat

See all Molidustat clinical trials

US Patents for Molidustat

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
Molidustat   Start Trial Method for the preparation of triazole compounds BAYER PHARMA AKTIENGESELLSCHAFT (Berlin, DE)   Start Trial
Molidustat   Start Trial Substituted dihydropyrazolones for treating cardiovascular and hematological diseases Bayer Intellectual Property GmbH (Monheim, DE)   Start Trial
Molidustat   Start Trial Substituted sodium 1H-pyrazol-5-olate Bayer Intellectual Property GmbH (Monheim, DE)   Start Trial
Molidustat   Start Trial Substituted dihydropyrazolones for treating cardiovascular and hematological diseases Bayer Intellectual Property GmbH (Monheim, DE)   Start Trial
Molidustat   Start Trial Substituted dihydropyrazolones for treating cardiovascular and hematological diseases Bayer Intellectual Property GmbH (Monheim, DE)   Start Trial
Molidustat   Start Trial Substituted dihydropyrazolones for treating cardiovascular and hematological diseases Bayer Intellectual Property GmbH (Monheim, DE)   Start Trial
Molidustat   Start Trial Substituted sodium-1H-pyrazole-5-olate Bayer Intellectual Property GmbH (Monheim, DE)   Start Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for Molidustat

Drugname Country Document Number Estimated Expiration Related US Patent
Molidustat Australia 2013258107 2032-05-08   Start Trial
Molidustat Canada 2872726 2032-05-08   Start Trial
Molidustat Chile 2014003003 2032-05-08   Start Trial
Molidustat Chile 2016001165 2032-05-08   Start Trial
Molidustat China 104411704 2032-05-08   Start Trial
Molidustat Colombia 7121324 2032-05-08   Start Trial
Molidustat Costa Rica 20140514 2032-05-08   Start Trial
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

AstraZeneca
Dow
Mallinckrodt
Colorcon
Medtronic
Express Scripts

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.